Medtekwiz Advisory led the round, which will fund clinical tests for Owlstone Medical's breathalyser in lung and colon cancer diagnostics.
UK-based chemical detection technology provider Owlstone has spun out a medical diagnostics subsidiary called Owlstone Medical with a $7m funding round led by Medtekwiz Advisory.
Owlstone Medical is developing, and plans to eventually commercialise a breathalyser for use in diagnosing conditions such as cancer, inflammatory and infectious disease. The capital will support clinical trials of the breathalyser for lung and colon cancer screening.
Billy Boyle, a co-founder of Cambridge University spinout Owlstone, is CEO of Owlstone Medical. He said: “Securing…
